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Abstract: Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients 
with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may 
offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 
months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such 'time for decision' is often unclear and 
the optimal duration of VKA remains debatable.  
In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can be of help to 
establish the optimal duration of VKA treatment; among them, the D-dimer (D-d) assay and the Residual Vein Thrombosis (RVT) as-
sessment by Compression Ultra-Sonography (CUS) were shown to be the most suitable. Studies’ results showed that negative results of 
these parameters after 3 to 6 months of therapy, identify a group of patients at low-risk for recurrent thrombosis in whom VKA treatment 
can be withheld. In the present review we will discuss advantages and potential limits of using these individual markers for the manage-
ment of patients with a first episode of DVT of the lower limbs. 
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RISK FOR RECURRENT THROMBOSIS ACCORDING TO 
THE NATURE OF THE INDEX EVENT 
 Long-term anticoagulant therapy of deep vein thrombosis 
(DVT) aims to complete the treatment of the acute episode and pre-
vent further recurrence of venous thrombo-embolism (VTE) [1]; 
low-molecular weight-heparin (LMWH) and oral vitamin K an-
tagonists (VKA) are the most commonly used effective drugs. The 
feasibility of long-term treatment with VKA is limited by the need 
for laboratory monitoring and dose adjustment, while parenteral 
administration is the main limitation for long-term therapy with 
LMWH; both these anticoagulants are associated with an increased 
risk of major bleeding [2]. Based on this assumption, it is reason-
able to stop anticoagulant treatment when the benefit of reducing 
recurrent VTE no longer outweighs the risk of major bleeding. 
However, such 'time for decision' is often unclear and the optimal 
duration of VKA treatment in patients with VTE remains debatable. 
 When deciding how long patients with VTE should be treated, 
we have to consider the risk of recurrence related to the index epi-
sode and this risk when VKA treatment is discontinued. Some stud-
ies have compared different durations of anticoagulant treatment, 
while others looked at the incidence of major clinical events after 
VTE, with the objective to identify risk factors useful to tailor anti-
coagulation. A third group of studies assessed the clinical value of 
markers useful for establishing the individual risk for recurrent 
VTE and, consequently, the optimal VKA duration. This annotation 
will deal with the results and clinical impact of studies using these 
different strategies in patients with a first episode of DVT of the 
lower limbs and treated with VKA. DVT may be associated with 
temporary risk factors (surgery, trauma, immobilization), with per-
sistent risk factors (cancer, paralysis, chronic diseases, etc.) or be 
unprovoked, occurring in the absence of any identifiable risk fac-
tors for thrombosis. 
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 The risk of recurrent VTE whilst on warfarin therapy is about 
1-3%. The risk of recurrent VTE after stopping anticoagulant ther-
apy markedly differs depending on whether the initial DVT was 
associated with one or more risk factors. In patients with a first epi-
sode of DVT, the estimated risk of recurrence after anticoagulant 
withdrawn is 8% if the index episode was idiopathic and 3% in case 
of provoked VTE [3-9]. Patients with cancer carry a higher rate of 
recurrence of up to 14·0% per year. In patients without transient 
risk factors, the risk for recurrent DVT persists for many years; the 
cumulative incidence of recurrent VTE is 17.5% after 2 years, 
24.6% after 5 years and 30.3% after 8 years [4]. These data apply 
even in patients in whom pulmonary embolism is the main manifes-
tation of VTE [8]. It is important to consider that, regardless of the 
nature of the index event, the risk of recurrence is higher early after 
discontinuation of anticoagulant therapy [4,5,10]. The specific risk 
for recurrent VTE associated with low-risk thrombophilia is un-
clear. Considering the specific role of the more common thrombo-
philic abnormalities with respect to the risk of recurrence, some 
evidence shows an increased odds for recurrent VTE of 1.72 (95% 
confidence interval [CI] 1.27-2.31) and of 1.41 (95% CI 1.14-1.75) 
for F2 G20210A (Prothrombin G20210A) and F5 R506Q (Factor V 
Leiden) respectively [11]. Others confirmed such results for F5 
R506Q only (relative risk [RR] 1·39; 95% CI 1·15-1·67) [12], while 
others did not [5,13,14]. At the present time, findings for low-risk 
thrombophilia do not justify the prolongation of anticoagulant and 
should remain an individual decision. Differently, in cases of high-
risk thrombophilia (double heterozygous or homozygous for F5 
R506Q, moderate/severe deficiency of antithrombin, protein C and 
S or presence of lupus anticoagulant) prolonged anticoagulation is 
indicated [5]. 
 Male gender has also been associated with an increased risk of 
recurrent VTE [13,15]. Overall, men have a higher risk than women 
(RR 1.6; 95% CI 1.2-2.0) to develop recurrent thrombosis after 
stopping anticoagulation [16]. Although some additional risk fac-
tors for recurrent venous thrombosis have been postulated (such as 
post-thrombotic syndrome), these parameters should not influence 
the duration of VKA [17]. 
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RISK FOR RECURRENCE ASSESSED ON INDIVIDUAL 
RISK  
 Several studies evaluated length of VKA treatment after DVT, 
all had differences in the diagnostic strategies, agents and regimens 
as well as risk stratification of patients. Some randomized trials 
were designed to evaluate whether the duration of anticoagulant 
treatment could be shortened to less than 3 months [3,18,19]; for 
this purpose, 4-6 weeks courses of anticoagulant treatment were 
compared with 3-6 months of therapy. During the follow-up, rang-
ing between 6 months and 1 year, the increase of the absolute risk 
with the shorter duration was approximately 8%; thus, the studies 
concluded that anticoagulant treatment should be continued for at 
least 3 months after an episode of DVT. 
 In recent studies, markers for the assessment of the individual 
risk for recurrent thrombosis have been proposed, which can be of 
help to establish the optimal duration of VKA treatment; among 
them, the D-dimer (D-d) assay and the RVT assessment by CUS 
were shown to be the most suitable [21-23]; In the DACUS study 
[24], patients with a first episode of deep vein thrombosis, treated 
with OAT for 3 months, were managed according to RVT findings. 
Those with RVT were randomized to either stop or continue antico-
agulants for 9 additional months, whereas in those without RVT, 
OAT was stopped. Of the 78 (30.2%) patients without RVT, only 1 
(1.3%; 0.63% person-years) had a recurrence. The adjusted HR of 
patients with RVT versus those without was 24.9 (95% CI, 3.4-
183.6; P = .002). Absence of RVT was used to identify a substantial 
subset of patients (at least 30% of patients with unprovoked DVT) 
characterized by a low risk of recurrent VTE who require a short-
term antithrombotic treatment.  
 In the Aesopus study [26], authors evaluated 538 consecutive 
patients with acute proximal DVT who were randomized to receive 
either a flexible duration of VKA (up to 1 year in patients with sec-
ondary DVT, up to 2 years in those with idiopathic DVT) based on 
persistence or regression of ultrasound confirmed residual thrombi 
at regular follow-up visits, or a fixed duration (3 months in patients 
with secondary DVT, 6 months in those with idiopathic DVT). All 
patients were followed up to 3 years to assess the development of 
recurrent VTE. During the 3-year follow-up period, recurrent VTE 
developed in 32 of the 271 patients (11.8%) randomized to the 
flexible duration, and in 46 of the 267 (17.2%) randomized to the 
fixed duration of VKA. In a multivariate analysis including age, 
gender, type of DVT, clinical symptoms of pulmonary embolism, 
and thrombophilia, the hazard ratio of developing recurrent VTE in 
patients randomized to the flexible as compared to those allocated 
to the fixed duration of VKA was 0.62 (95% CI, 0.39 to 0.97; p = 
0.036). When the effect and the duration of VKA was included in 
the model, the hazard ratio became 0.79 (95% CI, 0.50 to 1.26; p = 
0.32). During the period of anticoagulation, clinically relevant 
bleeding developed in 4 patients (1.5%) randomized to the flexible 
duration of warfarin and in 2 (0.7%) allocated to the fixed duration. 
The Author’s conclusion were that tailoring the duration of antico-
agulation based on the persistence of residual thrombi reduces the 
rate of recurrent VTE without an appreciable increase in the hemor-
rhagic risk.  
 D-dimer assay has been proven to be effective in similar clini-
cal settings. In the Prolong study [20], authors performed D-dimer 
testing 1 month after the discontinuation of anticoagulation in pa-
tients with a first unprovoked proximal deep-vein thrombosis or 
pulmonary embolism who had received a vitamin K antagonist for 
at least 3 months. Patients with a normal D-dimer level did not re-
sume anticoagulation, whereas those with an abnormal D-dimer 
level were randomly assigned either to resume or to discontinue 
treatment. Patients with an abnormal D-dimer level 1 month after 
the discontinuation of anticoagulation have a significant incidence 
of recurrent venous thromboembolism, which is reduced by the re-
sumption of anticoagulation. However, it is unknown whether D-d 
changes subsequently. Therefore, the aim of Prolong study II [25]  
was to assess  D-d time course and its relation with late recurrences 
in patients with normal D-d 1 month after anticoagulation suspen-
sion for a first episode of unprovoked VTE. Patients with a normal 
D-d 1 month after stopping anticoagulation repeated D-d testing 
every 2 months for 1 year. D-d was normal in 68% (243/355) of 
patients 1 month after anticoagulation suspension. Patients in whom 
D-d became abnormal at the third month and remained abnormal 
afterward had a higher risk of recurrence (7/31; 27% patient years; 
95% confidence interval [CI]: 12-48) than patients in whom D-d 
remained normal at the third month and afterward (4/149; 2.9% pa-
tient years; 95% CI: 1-7; adjusted hazard ratio: 7.9; 95% CI: 2.1-30; 
P = .002). 
 However, these trials had some drawbacks: in the PROLONG 
study, D-d assay was performed after VKA interruption [20] and in 
RVT investigations [21,22] study cohorts comprised also provoked 
DVT patients. As a matter of fact, none of these studies has offered 
clear-cut results useful to assess the optimal duration of VKA 
treatment.  
 For addressing these issues, we conducted a prospective man-
agement study (the Extended-DACUS) [27] where was investigated 
the risk-benefit ratio of an RVT-based VKA duration approach in 
patients with a first episode of idiopathic DVT of the lower limbs. 
Briefly, in patients without RVT, VKA was suspended after 3 
months while in those with RVT, VKA was continued for addi-
tional 15 or 21 months. Among 548 patients, 29.9% did not have 
RVT and VKA was stopped; the remaining patients continued anti-
coagulants up to 18 or 2 years. During treatment, the rate of recur-
rent VTE was 0% in RVT-negative and 7.4% and 6.5% in RVT-
positive groups, treated for 18 and 24 months respectively. Rate of 
major bleeding was 0%, 0.9% and 1.2% among the above reported 
groups. After VKA suspension, rate of recurrent events growth up 
to 1.2% in RVT-negative and up to 14.5% and 10% in RVT-
positive group treated for 18 and 24 months.  These results indicate 
that in patients without RVT, a short VKA treatment is sufficient; 
in those with persisting RVT, treatment duration extended to 2 
years substantially reduces, but not abolishes, the risk of thrombosis 
recurrence. 
DIFFERENT STRATEGIES FOR SECONDARY PREVEN-
TION 
 In order to avoid the risk for bleeding complications and the 
inconvenience of extended or indefinite VKA treatment, some in-
vestigators looked at low-intensity VKA for secondary prevention 
of recurrent VTE. Two trials evaluated the opportunity to extend 
oral anticoagulation with low-intensity warfarin (INR 1.5-2.0) after 
an initial treatment of 3-6 months of conventional-intensity antico-
agulation (INR 2·0-3·0) [27, 28]. The first study showed superior 
efficacy of a low-intensity anticoagulant regimen compared to pla-
cebo in the prevention of recurrent VTE, but the second investiga-
tion, which compared a conventional regimen to less-intensive ther-
apy, showed that the latter approach was less effective without re-
ducing major bleeding. At the present, extending anticoagulant 
treatment with reduced level of anticoagulation does not seems to 
be a worthy approach. 
ROLE OF RVT IN THE TREATMENT OF CANCER-
RELATED DEEP VEIN THROMBOSIS 
 Patients with cancer have a substantial risk for VTE recurrence 
as well as for bleeding complications while on long-term VKA 
[29], thus making LMWH the best therapeutic option in the acute 
and long-term treatment of cancer-related DVT [30-32]. Current 
guidelines suggest that such patients should be treated for at least 
6 months or longer if cancer is active [32] 
 However, the major limitation of the available information on 
cancer-related DVT is that it does not enable thrombotic risk strati-
fication according to type and tumor burden. Therefore, even in 
cancer patients, the possibility of an individual assessment for VTE 
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risk is highly recommended. For this purpose, the role of an RVT-
based strategy in patients with cancer-related DVT has been re-
cently evaluated [personal communication, interim analysis of the 
Cancer-DACUS]. Patients received LMWH for 6 months, adminis-
tered at therapeutic dosage for the first month and then reduced by 
25% in the next 5 months [21]. At this time, patients with RVT 
were randomized to continue anticoagulants for 6 additional months 
(Group A1) or to stop (Group A2), while patients without RVT 
stopped LMWH (Group B). Outcomes were recurrent VTE and/or 
major bleeding. Over a period of 24 months, 227 patients were 
evaluated across 12 centres in Italy; RVT was detected in 162 
(71.3%) patients; 79 patients were randomized to continue antico-
agulation while the remaining 83 were randomized to stop it. RVT 
was absent in 65 patients. Recurrent events occurred in 22.8% 
(31.6% person-year) of those who discontinued and 13.9% (20.6% 
person-year) of those who continued LMWH. In patients without 
RVT, recurrent VTE occurred in 3% (4.1% person-year) of pa-
tients. The adjusted HR for age and sex for Group A2 versus A1 
and Group B versus A1 was 1.58 (95% CI 0.85-2.93; P = .145) and 
4.54 (CI 2.3-6.66; P = 0.028), respectively. One major bleeding 
event occurred in each group of patients who stopped (Group A2 
[1.5%] and B [2.1%]) and 3 (3.8%) in those who continued antico-
agulation. Overall, 31 (23·1%) patients died due to cancer progres-
sion after a median follow-up of 13·2 months after randomization. 
CONCLUSIONS 
 The long-term duration of VKA after a first episode of DVT of 
the lower limbs is still debated. The estimation of the risk of recur-
rent DVT is essential for establishing length of anticoagulants; this 
risk can be related to the index episode or to the intrinsic patient’s 
risk for recurrent VTE and/or for bleeding complications. Accord-
ingly to the first consideration, patients with idiopathic DVT should 
receive at least 3 months of anticoagulants while those with tran-
sient risk factor 3 months or less. Based on intrinsic patient’s risk, 
treatment with a VKA should be tailored on the results of markers 
assessing individual thrombotic risk at the end of conventional 
treatment. Such markers are now available: absence of RVT or per-
sistently negative D-dimer allow the withdrawn of VKA, no matter 
the type of the index DVT. In contrast, presence of RVT at the end 
of minimum period of anticoagulation (3 months of VKA in case of 
idiopathic DVT or 6 month of LMWH in case of cancer-related 
thrombosis) require at least 2 years of anticoagulation (Table 1). 
 In conclusion, after 3 months of VKA physicians have to estab-
lish the risk-benefit ratio of continuing long-term anticoagulation. 
Detection of individual parameters may help in this decision but 
scheduled periodic re-assessment of the benefit from extending an-
ticoagulation is needed. 
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